😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

FDA confirms robotic prostatectomy survival rates match traditional surgery

EditorBrando Bricchi
Published 2024-06-05, 01:38 p/m
ISRG
-

SUNNYVALE, Calif. - The U.S. Food and Drug Administration (FDA) has approved a labeling revision for Intuitive's da Vinci X and Xi surgical systems, indicating that survival rates for patients undergoing robotic-assisted radical prostatectomy are comparable to those of traditional open surgery. The decision, announced today by Intuitive (NASDAQ:ISRG), is based on a review of real-world evidence (RWE) from a study of nearly 25,000 patients between 2007 and 2014.

The study, which compared the outcomes of robotic-assisted surgery to open surgery for treatment-naive prostate cancer patients, aimed to eliminate potential biases from the COVID-19 pandemic by selecting a timeframe prior to the global health crisis. Intuitive's Chief Medical Officer, Myriam Curet, M.D., highlighted the significance of this development, stating that it confirms the non-inferiority of the robotic system in terms of overall survival at 10 years.

The labeling change specifically updates the Precaution for Representative Uses statement for the da Vinci systems, now including an evaluation of outcomes related to cancer treatment, such as overall survival for radical prostatectomy. This adjustment reflects the FDA's recognition of the study's findings.

Intuitive's collaboration with the FDA, healthcare analytics firm Aetion, and the National Evaluation System for health Technology (NEST) utilized NEST's Mark process to validate the use of RWE in the labeling revision submission. This collaborative effort demonstrates the potential for similar long-term survival assessments for other cancer procedures, which could further advance regulatory science.

The da Vinci surgical systems, known for their high-definition 3D vision and precise instrumentation, have been designed to aid surgeons in minimally invasive procedures. Intuitive, a pioneer in robotic surgery, continues to focus on improving patient outcomes and advancing care delivery.

This labeling update is a testament to the company's ongoing commitment to providing data-driven evidence to support the effectiveness of its technologies. The information for this article is based on a press release statement from Intuitive.

InvestingPro Insights

As Intuitive (NASDAQ:ISRG) receives FDA approval for a significant labeling revision, it's an opportune moment to delve into the company's financial health and market performance. Intuitive's market capitalization stands robust at $144.23 billion, reflecting its substantial presence in the industry. The company's P/E ratio is currently high at 71.91, indicating a premium that investors are willing to pay for its earnings, perhaps in part due to the innovative nature of its technologies and the recent positive regulatory developments.

InvestingPro data shows a strong revenue growth of 13.81% over the last twelve months as of Q1 2024, suggesting that Intuitive is not just innovating, but also effectively monetizing its advancements. Additionally, the gross profit margin is impressive at 66.43%, which is indicative of the company's ability to manage its cost of goods sold and maintain profitability. Intuitive's stock is trading near its 52-week high, with the price at 98.62% of this peak, which may be a reflection of investor confidence following the FDA's nod.

Among the numerous InvestingPro Tips available, two particularly stand out for Intuitive: the company's stock generally trades with low price volatility, which might appeal to investors looking for stable growth opportunities in the healthcare tech sector. Furthermore, Intuitive has been profitable over the last twelve months, reinforcing the company's financial stability and the potential for sustained growth.

For readers interested in a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into Intuitive's performance and outlook. To explore these tips and benefit from the full suite of analytical tools, consider using the promo code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. With the upcoming earnings date set for July 18, 2024, staying informed with the latest data and expert analysis could be invaluable for those invested in Intuitive's journey.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.